[89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors
2024

[89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors

publication Evidence: moderate

Author Information

Author(s): Sanwick Alexis M., Haugh Katherine N., Williams Evan J., Perry Kala A., Thiele Nikki A., Chaple Ivis F.

Primary Institution: University of Tennessee, Knoxville

Hypothesis

This work aims to develop a novel 89Zr-labeled tracer incorporating the SSA, octreotide (TOC), for positron emission tomography (PET) imaging of SSTR+ NETs.

Conclusion

[89Zr]Zr-DFO-TOC was synthesized with high radiochemical yields and demonstrated potential for imaging SSTR+ NETs.

Supporting Evidence

  • The radiochemical yield was maintained at ≥ 95% for the new tracer.
  • In vitro studies showed significant differences in tracer uptake among different cell lines.
  • The compound remained stable in vitro for extended periods.

Takeaway

Scientists created a new imaging tool that helps doctors see certain tumors better using a special radioactive substance.

Methodology

In vitro studies were conducted using various cell lines to assess receptor binding and internalization of the radiotracer.

Limitations

Further in vivo studies are needed to validate the findings.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/s41181-024-00320-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication